In 2018, EMA approved GO for patients >15 years with previously untreated, de novo CD33-positive AML, at 3 mg/m2 (up to 5 mg) on days 1, 4, and 7 + DNR 60 mg/m2/day on days 1 to 3, and Ara-C 200 mg/m2/day by continuous infusion on days 1 to 7 [62,63]. The gene discussed is CD33; the disease is acute myeloid leukemia.